Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Lyra Therapeutics Inc. LYRA

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.


Recent & Breaking News (NDAQ:LYRA)

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire September 13, 2022

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

PR Newswire September 13, 2022

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

PR Newswire September 10, 2022

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

PR Newswire September 8, 2022

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

PR Newswire September 6, 2022

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

PR Newswire August 29, 2022

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 9, 2022

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

PR Newswire July 5, 2022

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

PR Newswire July 5, 2022

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire June 17, 2022

Lyra Therapeutics to Present at Upcoming Investor Conferences

PR Newswire May 26, 2022

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 10, 2022

Lyra Therapeutics to Present at Upcoming Investor Conferences

PR Newswire May 5, 2022

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

PR Newswire April 29, 2022

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

PR Newswire April 25, 2022

Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022

PR Newswire April 21, 2022

Lyra Therapeutics Announces Closing of $100.5 Million Private Placement

PR Newswire April 13, 2022

Lyra Therapeutics Announces $100.5 Million Private Placement

PR Newswire April 8, 2022

Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

PR Newswire March 9, 2022

Lyra Therapeutics Appoints Jim Tobin to Board of Directors

PR Newswire March 7, 2022